Research data, trial funding and new discovery infrastructure

1. EU earmarks funding to sustain essential life-sciences data¹

The European Commission announced a €65 million Horizon Europe package on 6 October to sustain data resources used in drug discovery and biotechnology. The amended work programme earmarks €19 million for GENCODE, €30 million for UniProt and €8 million for Europe PMC, with a further €8 million competitive call for other repositories and services. The support covers curation, maintenance and continuity of open access. Grant agreements still require evaluation. For researchers building molecular models or tracing evidence, the practical value is preserving foundational resources rather than announcing a new predictive system.¹

2. Australia announces up to A$136 million for clinical trials²

Australia’s health department announced a Medical Research Future Fund opportunity of up to A$136 million on 6 October. Four streams cover trial feasibility and full trials for rare cancers, rare diseases and unmet needs, studies addressing evidence gaps in health technology assessment, and prevention trials. The programme supports national and international clinical research, creating routes to test interventions where existing options or evidence are inadequate. These are funding opportunities, not awards already made or proof that a treatment works. Researchers should consult the official grant documentation for eligibility and application details.²

3. Sensible finances cell-based mRNA design and manufacturing³

Sensible Biotechnologies announced a $47 million financing package on 6 October to expand its mRNA technology. The package includes a Series A led by Oxford Science Enterprises and up to $20 million in non-dilutive funding from Slovakia and the European Union. The company plans to scale VECTOR, which combines computational sequence design, automated screening and mRNA production in engineered living cells, and develop clinical-grade manufacturing capabilities. This links design decisions with the practical problem of producing RNA medicines. The announcement describes funded development plans; it does not establish clinical benefit or completed manufacturing validation.³

4. OmniAb widens screening access and introduces peptide discovery⁴

OmniAb announced on 6 October that its xPloration instrument will become available for purchase by all customers this month, extending access beyond the partner programme introduced in 2025. The company describes a system that combines single B-cell screening, automated imaging and computer vision with recovery of selected cells for sequencing. It also introduced OmniTides, a peptide-discovery offering using its transgenic chicken platform and a workflow linking discovery to synthesis through qualified contractors. Broader access could expand experimental choices for antibody and peptide programmes. These are company descriptions of capabilities and rollout plans; the announcement provides no independent comparative performance assessment.⁴

5. Digital CMC Consortium launches wider standards collaboration⁵

The Digital CMC Consortium announced its public launch on 6 October, following a year of proof-of-concept work. The industry collaboration aims to make chemistry, manufacturing and controls information reusable across pharmaceutical developers, contractors and technology providers. Its initial focus is technology transfer between sponsors and contract development and manufacturing organisations, using structured data models, templates and implementation tools. Participants include leaders from Novartis, Takeda and Thermo Fisher Scientific. Shared formats could reduce repeated manual translation of manufacturing knowledge. The release describes an adoption effort and work in progress, rather than demonstrating completed industry-wide interoperability or measured development-time savings.⁵